<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02009501</url>
  </required_header>
  <id_info>
    <org_study_id>VAC/09/05/ULTA</org_study_id>
    <nct_id>NCT02009501</nct_id>
  </id_info>
  <brief_title>V.A.C. VeraFlo™ Instillation Therapy vs V.A.C. Ulta™ Therapy on Biofilm in Chronically Infected Wounds</brief_title>
  <official_title>A Prospective, Open, Comparative, Randomized Single-center Study to Evaluate the Effect of V.A.C. VeraFlo™ Therapy With .125% Dakins vs V.A.C. Ulta™ Therapy on Biofilm Removal/Disruption/Elimination in Chronically Infected Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kinetic Concepts, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study would like to determine if using negative pressure wound therapy with an
      instillation of .125% Dakins is more effective than using negative pressure wound therapy
      alone on biofilm removal, disruption and elimination in chronically infected lower extremity
      wounds.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bacteria Colony-forming Units Using When NPWT and NPWTi on Venous Leg Ulcers</measure>
    <time_frame>Baseline and day 7</time_frame>
    <description>Biopsies for bacteria colony-forming units obtained at pre surgical debridement (baseline) and day 7.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Lower Extremity Wound Infected</condition>
  <condition>Venous Stasis Ulcers</condition>
  <arm_group>
    <arm_group_label>VAC VeraFlo with Dakins Instillation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VAC VeraFlo with Dakins .125% instillation will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VAC Ulta Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>VAC ULTA Therapy will be initially applied in the OR after surgical debridement. Dressing will be changed on day 4 and and removed on day 7. Wound assessments will continue at weeks 2, 3, and 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VAC VeraFlo with Dakins Instillation</intervention_name>
    <description>VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.</description>
    <arm_group_label>VAC VeraFlo with Dakins Instillation</arm_group_label>
    <other_name>NPWTi</other_name>
    <other_name>VAC Instill</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>VAC Ulta Therapy</intervention_name>
    <description>VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.</description>
    <arm_group_label>VAC Ulta Therapy</arm_group_label>
    <other_name>VAC</other_name>
    <other_name>NPWT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient is of 18 years or older.

          -  Males and females - provided they are not pregnant and if of reproductive age are
             using contraception.

          -  Patient with ulcers that:

               1. Have an ulcer area of at least 4 cm2 confirmed via counting squares on an wound
                  tracing

               2. Have been present for at least 4 weeks

               3. Are confirmed to have a colony forming unit per gram of wound tissue greater than
                  or equal to 10 to the 5th cfu

               4. Are full thicknesses through to dermal or subcutaneous tissue but not extending
                  to muscle or bone.

               5. The patient has an ABI of greater or equal to 0.8 and lower than 1.3 or has a
                  suitable Peripheral Vascular Resistance (PVR) and Doppler assessment which
                  confirms venous disease &amp; therefore treatment with Profore is deemed acceptable
                  by the clinician.

               6. The patient has one or more clinical signs of infection (edema, malodor,
                  local/periwound erythema, spontaneous pain between dressing changes, increased
                  exudate, discoloration of granulation tissue, increased temperature at wound, non
                  progression of wound, purulent exudate and friable granulation tissue)

               7. The patient is able to understand the evaluation and is willing to consent to the
                  evaluation.

               8. Patients with a suitable wound on a different limb to any other wounds previously
                  eligible.

        Exclusion Criteria:

          1. Patients undergoing chemotherapy

          2. Patients being treated with immunosuppressive drugs or corticosteroids

          3. Patients with an autoimmune disease

          4. Patients who have participated in an experimental drug or device study within the last
             15 days

          5. Patients that have been entered in this evaluation previously as an evaluable patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John C Lantis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's-Roosevelt Hospital Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Luke's-Roosevelt Hospital Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 24, 2013</study_first_submitted>
  <study_first_submitted_qc>December 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 12, 2013</study_first_posted>
  <results_first_submitted>February 22, 2018</results_first_submitted>
  <results_first_submitted_qc>November 23, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 27, 2018</results_first_posted>
  <last_update_submitted>November 23, 2018</last_update_submitted>
  <last_update_submitted_qc>November 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infected wounds</keyword>
  <keyword>NPWTi</keyword>
  <keyword>VAC Instill</keyword>
  <keyword>Biofilm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began Nov 2013, with enrollment in Jan 2014 and trial conducted to Nov 2014. All patients were recruited from the outpatient vascular and wound care clinic at Mt Sinai St Luke’s – Roosevelt Hospitals in New York City.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>VAC Ulta Therapy</title>
          <description>VAC ULTA Therapy applied in the OR after surgical debridement.</description>
        </group>
        <group group_id="P2">
          <title>VAC VeraFlo With Dakins Instillation</title>
          <description>VAC VeraFlo with Dakins Instillation.0.125% instillation applied in the OR after surgical debridement.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>VAC Ulta Therapy</title>
          <description>VAC ULTA Therapy applied in the OR after surgical debridement.</description>
        </group>
        <group group_id="B2">
          <title>VAC VeraFlo With Dakins Instillation</title>
          <description>VAC VeraFlo with Dakins Instillation.0.125% instillation applied in the OR after surgical debridement.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.7" spread="2.4"/>
                    <measurement group_id="B2" value="62.3" spread="5.8"/>
                    <measurement group_id="B3" value="63.83" spread="4.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ulcer duration</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.9" spread="42.9"/>
                    <measurement group_id="B2" value="103.3" spread="43.3"/>
                    <measurement group_id="B3" value="99.07" spread="43.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ulcer size</title>
          <units>cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="10.8"/>
                    <measurement group_id="B2" value="56.2" spread="17.8"/>
                    <measurement group_id="B3" value="50.48" spread="16.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Etiology</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Venous</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidities</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hypertension</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diabetes Mellitus</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Morbid Obesity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic Kidney Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperlipidemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tobacco use</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Bacteria Colony-forming Units Using When NPWT and NPWTi on Venous Leg Ulcers</title>
        <description>Biopsies for bacteria colony-forming units obtained at pre surgical debridement (baseline) and day 7.</description>
        <time_frame>Baseline and day 7</time_frame>
        <group_list>
          <group group_id="O1">
            <title>VAC Ulta Therapy</title>
            <description>VAC ULTA Therapy applied in the OR after surgical debridement.</description>
          </group>
          <group group_id="O2">
            <title>VAC VeraFlo With Dakins Instillation</title>
            <description>VAC VeraFlo with Dakins Instillation.0.125% instillation applied in the OR after surgical debridement.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Bacteria Colony-forming Units Using When NPWT and NPWTi on Venous Leg Ulcers</title>
          <description>Biopsies for bacteria colony-forming units obtained at pre surgical debridement (baseline) and day 7.</description>
          <units>10^3 CFU/g</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.6" spread="8.8"/>
                    <measurement group_id="O2" value="12.9" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 days post application</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="5.0"/>
                    <measurement group_id="O2" value="3.2" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events not collected</desc>
      <group_list>
        <group group_id="E1">
          <title>VAC Ulta Therapy</title>
          <description>VAC ULTA Therapy applied in the OR after surgical debridement.</description>
        </group>
        <group group_id="E2">
          <title>VAC VeraFlo With Dakins Instillation</title>
          <description>VAC VeraFlo with Dakins Instillation.0.125% instillation applied in the OR after surgical debridement.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Limitation: small sample size and associated large data variance. Absence of a standardized biopsy schema given the heterogeneous distribution of biofilm-protected bacteria within wounds, may not properly capture effects of the treatment modalities.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. John C. Lantis II</name_or_title>
      <organization>Mount Sinai St. Luke's</organization>
      <email>JLantis@chpnet.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

